Pharmacyclics, listed as a new big biotech entrant in 2014, works to improve the lives of cancer affected patients by entering into strategic partnering deals to support its product pipeline. Read the full story

Headquartered in Dublin, Ireland Jazz Pharmaceuticals is a specialty biopharmaceuticals company that has undergone significant growth in recent years. Jazz Pharmaceuticals is focused upon delivering products for cataplexy, narcolepsy, oncology/leukemia, chronic pain and non-opioid schizophrenia.   Read the full story

NovaQuest Capital Management announced the final closing of NovaQuest Pharma Opportunities Fund III financing.

Read the full story

This year has seen a lower frequency in pharma merger and acquisition (M&A) activity with 255 deals announced in the first six months of 2012 compared to 199 deals this year (2013) according to Current Agreements Read the full story

3-V Biosciences announced the completion of a Series C financing round, raising $20 million. Read the full story

In a pharma partnering deal, Novartis Pharma AG, a big pharma company let the development rights of  Synacthen to Questcor Pharmaceuticals Read the full story

Amarin, a biopharmaceutical company,  was able to raise $100 million in non-equity financing that will help it form a sales force to launch its heart drug Vascepa. Read the full story

In a pharma partnering deal worth hundreds of millions of dollars, Protalix Biotherapeutics Inc.will sell its Gaucher's disease treatment to the government of Brazil Read the full story

In a public announcement, MethylGene declared its intention to complete a private financing placement in the United States of Cdn.$26.1 million Read the full story

Ambit Biosciences announced that the company has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib Read the full story